

**Description**

The user responsible for the EHR configuration updates the system with a new vaccine schedule

**Comments**

No Comments

**Pre-condition**

The EHR needs to be updated with a new immunization schedule for a vaccine product.

**Post-Condition**

The updated Patient Immunization Schedule for the vaccine product is available.

**Test Objectives**

**Update Patient Immunization Schedule:** The EHR or other clinical software system displays a patient's anticipated immunization schedule routinely and updates the patient's schedule when immunization guidelines change.

**Evaluation Criteria**

The EHR is able to update the patient immunization schedule for the following adult vaccine:

CVX:	208
Vaccine Name:	Pfizer-BioNTech Covid-19 Vaccine
Agegroup 12+	2-dose series separated by 21 days. A series started with Pfizer-BioNTech COVID-19 Vaccine should be completed with this product.
Moderately and severely immunocompromised people:	Administer an additional primary dose at least 28 days after the initial 2-dose primary series.
Booster Dose:	<p>Administer a booster dose at least 6 months after the last dose of a COVID-19 mRNA vaccine primary series (i.e., the 2nd dose or additional primary series dose for moderately or severely immunocompromised people).</p> <ul style="list-style-type: none"><li>• Should be given to people 18 years of age and older (use of heterologous – mix and match – booster doses is allowed; however, mRNA COVID-19 vaccines are preferred)</li><li>• May be given to people 16 and 17 years of age based on their individual benefits and risks</li></ul>

**Notes**

The vendor may leverage an external tool to support vaccine schedule information. If so, the vendor should provide documentation regarding how the schedule is updated, how the EHR vendor and providers are notified of the updated schedule, and where in the EHR the modification has impact.

These codes will be used to administer the new vaccine in later test steps.

It is acceptable to demonstrate without saving the information, and a substitute vaccine will be used later in the testing.

Should additional content be needed to complete the new record, the vendor may supply this detail, and the tester will document such information to inform future updates.

The vendor may need to show the screens and omit the commit action. If so, a substitute vaccine may be leveraged for later steps.

The tester shall document any additional comments or concerns identified by the vendor.

The test is the ability to enter the schedule and it may not reflect the current COVID schedule.

